Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
What happens to a manuscript after submission? How does the editor reach a decision? What is the editor’s role during peer review? We take a look into the editorial process at Nature Cancer.
The Biden administration has proposed a new agency to drive innovation in health research, including cancer. The focus on cancer and accelerated development is welcome, but for the time being, whether and how these plans will materialize is less clear.
Social media have emerged as a key communication tool for scientists. Here we explore how to reap the benefits and avoid the pitfalls of social networking.
The treatment of triple-negative breast cancer remains chemotherapy based and lacks targeted drugs. However, immunotherapy combinations have shown promising activity, targeted chemotherapy options via antibody–drug conjugates are in the clinic, and molecular means of identifying targetable subsets are on the horizon. This Clinical Outlook discusses current and future possibilities for treating triple-negative breast cancer.
Making data available is essential for validating and furthering scientific discoveries. Helping authors navigate whether, how and in what form to share the data is also essential.
The COVID-19 pandemic is proving a major setback for achieving gender equality. Post-pandemic recovery efforts must focus on supporting diversity and bridging the gender gap.
The deployment of molecular biomarkers that are indicative of sensitivity to tumor-targeted or immune-targeted cancer therapies improves the outcome of individual patients and increases the chances of successful drug approval. However, for many lethal malignancies, the majority of clinical trials are conducted with patients who do not have biomarkers and hence they miss the target.
Cancer therapies have evolved considerably in recent decades, substantially improving the quality of life and survival of patients with cancer. In this issue, we launch our Series on Cancer Therapy, exploring current paradigms and recent advances and challenges in this field, through specially commissioned articles.
Cancer research has undergone transformational changes over the past several decades. On the occasion of the 20th anniversary of the establishment of the NCI Center for Cancer Research, we highlight some elements that enable successful institutional approaches to solving the most pressing problems in cancer research.
The election of Joe Biden to the US presidency has rekindled optimism in the world of science. To truly bring science to center stage will require bold political moves, the pulling together of all stakeholders, and time.
The COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus, poses a clear and present danger to the health and well-being of populations. Here we discuss its indirect impact on global cancer prevention and control efforts, particularly for cervical cancer. We suggest some comparisons between the COVID-19 pandemic and the human papillomavirus–induced cancer burden, as well as opportunities for translating pandemic-control strategies into effective cancer control.
This month marks one year since the launch of Nature Cancer. As we celebrate our first anniversary, we reflect on the past year and thank the cancer research community for embracing our journal.
Inhibition of the anti-apoptotic protein BCL-2 has emerged as a highly effective treatment for acute myeloid leukemia; approved lower-intensity venetoclax combination therapies are now being rapidly incorporated into an improved standard of care for this cancer. Here we recount an abbreviated history of venetoclax for acute myeloid leukemia, focusing on a selection of key studies along the path from development into the clinic.
Recent preclinical and clinical research has led to exciting advances related to high-grade serous ovarian cancer, from examining its cellular origins to gaining insight into DNA-damage-repair mechanisms that may be leveraged for therapies. Furthermore, studies have demonstrated clinical benefit for inhibition of the polymerase PARP and modulation of the cell cycle, and have identified molecular features related to therapeutic response.
Precision oncology trials based on cancer biomarkers have the potential to improve outcomes by guiding the optimal choice of therapies for patients. For this to be truly achieved, computational methods such as virtual molecular tumor boards, dynamic precision medicine and digital twins are needed to support cohort selection and trial enrollment at scale.
As COVID-19 continues to surge, it is essential to understand and address the looming crisis of mental-health issues caused or exacerbated by the pandemic.
Beyond the suffering caused by the disease, most patients diagnosed with cancer in the USA face substantial financial hardships associated with their treatments. What underlies the financial toxicity of cancer?
